 RattanIndia Power Ltd consolidated Q2FY26 loss at Rs. 31.55 crores
RattanIndia Power Ltd consolidated Q2FY26 loss at Rs. 31.55 crores Dr Lal Path Labs Ltd reports Rs. 150.6 crores consolidated profit in Q2 FY26
Dr Lal Path Labs Ltd reports Rs. 150.6 crores consolidated profit in Q2 FY26 Sammaan Capital Ltd consolidated Q2 FY2025-26 net profit at Rs. 308.47 crores
Sammaan Capital Ltd consolidated Q2 FY2025-26 net profit at Rs. 308.47 crores Aptus Value Housing Finance India Ltd Q2 FY2026 consolidated PAT higher at Rs. 226.54 crores
Aptus Value Housing Finance India Ltd Q2 FY2026 consolidated PAT higher at Rs. 226.54 crores Sigma Solve Ltd Q2 FY2026 consolidated profit up at Rs. 6.64 crores
Sigma Solve Ltd Q2 FY2026 consolidated profit up at Rs. 6.64 crores 
              Dishman Pharmaceuticals & Chemicals Ltd has announced that the Board of Directors of the Company at its meeting held on May 14, 2007, has allotted 1,26,627 equity shares of Rs 2/- each of the Company at a premium of Rs 170/- per equity share upon exercise of option of conversion by the FCCB holders for conversion of 0.50% Foreign Currency Convertible Bonds (FCCB) of the principal amount of US$ 500,000 into the equity shares of the Company.
Consequently, the paid-up equity share capital of the Company has increased from 7,29,72,843 equity shares of Rs 2/- to 7,30,99,470 equity share of Rs 2/- each.